Protein Sciences Corporation, manufacturer of Flublok®, reports that Laboratorios Liomont, S.A. de C.V., a leading Mexican pharmaceutical company and licensee of Flublok for the Mexican market, has obtained approval from the Mexican regulatory agency COFEPRIS for Flublok for the prevention of influenza in adults 18 and older.

“We are very pleased with the rapid approval of Flublok® in Mexico and the approval of the longer shelf life,” said Manon Cox, President and CEO of Protein Sciences.  “Recombinant technology is the only technology that can produce an influenza vaccine with the precision to exactly match circulating flu strains.”